1139 studies were found. Here are studies 1 to 50.

1.		No longer recruiting	12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy. Condition: Hepatitis C
2.		Recruiting	17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer
3.		Completed	A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS Conditions: Cryptosporidiosis; HIV Infections
4.		Recruiting	3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
5.		Recruiting	3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer Conditions: unresectable extrahepatic bile duct cancer; recurrent gallbladder cancer; unresectable gallbladder cancer; recurrent extrahepatic bile duct cancer; ...
6.		Suspended	3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Conditions: stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer
7.		Recruiting	3-AP as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma (Cancer) of the Pancreas Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
8.		Recruiting	3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Conditions: recurrent esophageal cancer; stage IV esophageal cancer; Adenocarcinoma of the Esophagus
9.		Recruiting	4-PBA: Will it increase the level of Alpha 1-Antitrypsin(AAT) in persons with AAT deficiency? Condition: alpha 1-Antitrypsin Deficiency
10.		No longer recruiting	506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult T-cell leukemia/lymphoma; angioimmunoblastic T-cell lymphoma; ...
11.		No longer recruiting	6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Colorectal Cancer Conditions: recurrent colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent rectal cancer; ...
12.		No longer recruiting	6-Hydroxymethylacylfulvene in Treating Patients With Metastatic or Recurrent Colorectal Cancer Conditions: recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; ...
13.		No longer recruiting	6-Hydroxymethylacylfulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer Conditions: recurrent pancreatic cancer; stage III pancreatic cancer; stage IV pancreatic cancer; adenocarcinoma of the pancreas
14.		Completed	8-Day Safety, Tolerability, and Effects Study of Inhaled INS37217 and Placebo In Adult and Pediatric Cystic Fibrosis Patients Condition: Cystic Fibrosis
15.		Completed	Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens Conditions: Aniridia; Eye Abnormality; Ocular Hypertension; Open Angle Glaucoma
16.		Recruiting	ABT-751 in Treating Young Patients With Refractory Solid Tumors Condition: childhood cancer
17.		Recruiting	ABX-EGF in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Chemotherapy Conditions: adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; ...
18.		Recruiting	ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Conditions: Colorectal Cancer; Metastases
19.		Recruiting	Active Crohn’s Disease Study Condition: Crohn Disease
20.		Completed	Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer Conditions: stage III pancreatic cancer; recurrent pancreatic cancer; Pain; stage IVA pancreatic cancer; stage IVB pancreatic cancer
21.		Recruiting	Acupuncture for Irritable Bowel Syndrome Condition: Irritable Bowel Syndrome
22.		Recruiting	Acupuncture for Irritable Bowel Syndrome (IBS) Condition: Irritable Bowel Syndrome
23.		Recruiting	Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus) Conditions: Ileus; Neoplasms
24.		Recruiting	Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer Condition: Colorectal Neoplasms
25.		Recruiting	Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Crohn’s Disease Condition: Crohn's Disease
26.		No longer recruiting	Addition of ISIS 14803 to Therapy with Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) patients not Responding Adequately to the Two Drugs Condition: Hepatitis C, Chronic
27.		Completed	Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients Conditions: Hepatitis B; HIV Infection
28.		Recruiting	Adjuvant Chemoradiotherapy and Interferon alfa in Treating Patients With Resected Pancreatic Cancer Conditions: stage I pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; adenocarcinoma of the pancreas
29.		Recruiting	Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer Conditions: Colon Cancer; liver metastases; Rectal Cancer
30.		Recruiting	Adjuvant Oxaliplatin and Capecitabine Compared With Fluorouracil and Leucovorin in Treating Chemotherapy-Naïve (Not Previously Treated) Patients Who Have Undergone Resection for Stage III Colon Cancer Condition: stage III colon cancer
31.		Recruiting	Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Conditions: adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer; Pain
32.		Recruiting	AG2037 in Treating Patients With Metastatic Cancer of the Colon or Rectum That Has Not Responded to Fluorouracil and Leucovorin Conditions: recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; Stage IV rectal cancer; adenocarcinoma of the colon; ...
33.		Recruiting	Alanosine in Treating Patients With Cancer Conditions: Gastrointestinal Cancer; musculoskeletal cancer; Osteosarcoma; thorax and respiratory cancer
34.		No longer recruiting	Alicaforsen (ISIS 2302) in Patients with Active Crohn’s Disease Condition: Crohn's Disease
35.		No longer recruiting	Alicaforsen (ISIS 2302) in Patients with Active Crohn’s Disease Condition: Crohn's Disease
36.		No longer recruiting	Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer Conditions: recurrent colon cancer; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer
37.		No longer recruiting	Amifostine to Protect From the Side Effects of Peripheral Stem Cell Transplantation in Treating Patients With High-Risk or Relapsed Solid Tumors Conditions: childhood soft tissue sarcoma; childhood liver cancer; adult soft tissue sarcoma; Bone Cancer; ovarian sarcoma; Testicular Cancer; Brain Tumor; ...
38.		No longer recruiting	Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity Conditions: Gastrointestinal Cancer; Pancreatic Cancer; Liver Cancer; Female Reproductive Cancer
39.		Completed	Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus Conditions: recurrent gastric cancer; stage III gastric cancer; stage IV gastric cancer; stage III esophageal cancer; stage IV esophageal cancer; ...
40.		Recruiting	Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer Conditions: Anal Cancer; perioperative and postoperative complications; Rectal Cancer
41.		Recruiting	Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus Conditions: stage IV esophageal cancer; recurrent esophageal cancer; Adenocarcinoma of the Esophagus
42.		No longer recruiting	Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine Conditions: small intestine adenocarcinoma; recurrent small intestine cancer
43.		Recruiting	Antineoplaston Therapy in Treating Patients With Colon Cancer Conditions: stage IV colon cancer; recurrent colon cancer; adenocarcinoma of the colon
44.		No longer recruiting	Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer Conditions: stage IV colon cancer; recurrent colon cancer; adenocarcinoma of the colon
45.		Recruiting	Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Conditions: Merkel Cell Carcinoma; Islet Cell Carcinoma; Neuroendocrine Carcinoma; Pituitary Tumor
46.		No longer recruiting	Antineoplaston Therapy in Treating Patients With Primary Liver Cancer Conditions: stage IV childhood liver cancer; recurrent childhood liver cancer; advanced adult primary liver cancer; recurrent adult primary liver cancer
47.		Recruiting	Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer Conditions: recurrent pancreatic cancer; adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer
48.		No longer recruiting	Antineoplaston Therapy in Treating Patients With Stomach Cancer Conditions: stage III gastric cancer; stage IV gastric cancer; recurrent gastric cancer; adenocarcinoma of the stomach
49.		No longer recruiting	Aroplatin and Capecitabine in Patients with Advanced Colorectal Cancer Resistant to Standard Therapies Condition: Colorectal Neoplasms
50.		No longer recruiting	Aroplatin and Gemcitabine in Patients with Advanced Pancreatic Cancer Resistant to Standard Therapies Condition: Pancreatic Neoplasms